Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer.
Humans
Colorectal Neoplasms
/ drug therapy
Male
Trifluridine
/ therapeutic use
Female
Cachexia
/ drug therapy
Middle Aged
Aged
Bevacizumab
/ therapeutic use
Thymidine Phosphorylase
/ antagonists & inhibitors
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Neoplasm Metastasis
Treatment Outcome
Adult
Aged, 80 and over
Bevacizumab
CXI
Cachexia
Colorectal cancer
FTD/TPI
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
22
08
2024
accepted:
24
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
In later-line treatment of metastatic colorectal cancer (mCRC), there may be large differences in treatment efficacy depending on cancer cachexia. Recently, the cachexia index (CXI), which was calculated from the skeletal muscle mass index (SMI), serum albumin concentration, and neutrophil-to-lymphocyte ratio, was developed to evaluate cancer cachexia. We retrospectively examined the CXI of 80 patients who were treated with trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) + bevacizumab (Bmab) therapy as a later-line treatment for mCRC, and assessed the impact of cancer cachexia on chemotherapeutic efficacy using CXI. Progression-free and overall survival rates were significantly worse in the low CXI group than in the high CXI group, although there were no marked differences in tumor factors, such as the number of metastatic organs or gene mutations, between the two groups. As the cross-sectional area of the iliopsoas muscle was significantly associated with that of the skeletal muscle, the accuracy of the CXI based on the psoas mass index (P-CXI), which is easier to calculate than the SMI, in predicting treatment outcomes was equivalent to that of the CXI based on the SMI (S-CXI). Cancer cachexia is an important factor related to treatment efficacy in later-line treatments, such as FTD/TPI + Bmab therapy.
Identifiants
pubmed: 39468284
doi: 10.1038/s41598-024-77766-z
pii: 10.1038/s41598-024-77766-z
doi:
Substances chimiques
Trifluridine
RMW9V5RW38
Bevacizumab
2S9ZZM9Q9V
Thymidine Phosphorylase
EC 2.4.2.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25884Informations de copyright
© 2024. The Author(s).
Références
Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl. J. Med. 372, 1909–1919 (2015).
doi: 10.1056/NEJMoa1414325
pubmed: 25970050
Prager, G. W. et al. SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl. J. Med. 388, 1657–1667 (2023).
doi: 10.1056/NEJMoa2214963
pubmed: 37133585
Shibutani, M. et al. Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. Anticancer Res. 40, 4157–4163 (2020).
doi: 10.21873/anticanres.14415
pubmed: 32620665
Kotani, D. et al. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. 19, 1253 (2019).
doi: 10.1186/s12885-019-6475-6
pubmed: 31881856
pmcid: 6935149
Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489–495 (2011).
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
da Rocha, I. M. G. et al. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J. Cachexia Sarcopenia Muscle. 10, 445–454 (2019).
doi: 10.1002/jcsm.12391
pubmed: 30924270
pmcid: 6463470
Jafri, S. H., Previgliano, C., Khandelwal, K. & Shi, R. Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients. Clin. Med. Insights Oncol. 9, 87–93 (2015).
doi: 10.4137/CMO.S30891
pubmed: 26604850
pmcid: 4640427
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Nakashima, K. et al. Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancer. Ann. Gastroenterol. Surg. 7, 733–740 (2023).
doi: 10.1002/ags3.12669
pubmed: 37663966
pmcid: 10472360
Yan, X. L. et al. Comparison of the cachexia index based on hand-grip strength (H-CXI) with the original CXI for the prediction of cancer cachexia and prognosis in patients who underwent radical colectomy for colorectal cancer. Front. Nutr. 11, 1290299 (2024).
doi: 10.3389/fnut.2024.1290299
pubmed: 38445206
pmcid: 10912503
Matsunaga, T. et al. Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study. Surg. Today. 54, 231–239 (2024).
doi: 10.1007/s00595-023-02721-w
pubmed: 37526733
Brown, L. R. et al. Cachexia index for prognostication in surgical patients with locally advanced oesophageal or gastric cancer: multicentre cohort study. Br. J. Surg. 111, znae098 (2024).
doi: 10.1093/bjs/znae098
pubmed: 38593042
pmcid: 11003541
Evans, W. J. et al. Cachexia: a new definition. Clin. Nutr. 27, 793–799 (2008).
doi: 10.1016/j.clnu.2008.06.013
pubmed: 18718696
Fujii, H. et al. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. Anticancer Res. 40, 7067–7075 (2020).
doi: 10.21873/anticanres.14734
pubmed: 33288604
Watanabe, H. & Oshima, T. The Latest Treatments for Cancer Cachexia: An Overview. Anticancer Res. 43, 511–521 (2023).
doi: 10.21873/anticanres.16188
pubmed: 36697073
Hojman, P. et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am. J. Physiol. Endocrinol. Metab. 301, E504–510 (2011).
doi: 10.1152/ajpendo.00520.2010
pubmed: 21653222
Aoi, W. et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 62, 882–889 (2013).
doi: 10.1136/gutjnl-2011-300776
pubmed: 22851666
Temel, J. S. et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519–531 (2016).
doi: 10.1016/S1470-2045(15)00558-6
pubmed: 26906526
Crawford, J. Clinical results in cachexia therapeutics. Curr. Opin. Clin. Nutr. Metab. Care. 19, 199–204 (2016).
pubmed: 26974316
Tanji, Y. et al. Significant impact of cachexia index on the outcomes after hepatic resection for colorectal liver metastases. Ann. Gastroenterol. Surg. 6, 804–812 (2022).
doi: 10.1002/ags3.12578
pubmed: 36338593
pmcid: 9628226
Kamada, T. et al. Prognostic significance of the cachexia index in patients with stage I-III colorectal cancer who underwent laparoscopic surgery. Surg. Today. 53, 1064–1072 (2023).
doi: 10.1007/s00595-023-02646-4
pubmed: 36725756
Abbass, T., Tsz Ho, Y. T., Horgan, P. G., Dolan, R. D. & McMillan, D. C. The relationship between computed tomography derived skeletal muscle index, psoas muscle index and clinical outcomes in patients with operable colorectal cancer. Clin. Nutr. ESPEN. 39, 104–113 (2020).
doi: 10.1016/j.clnesp.2020.07.010
pubmed: 32859302
Portal, D. et al. L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients. Cancer Manag Res. 11, 2579–2588 (2019).
doi: 10.2147/CMAR.S195869
pubmed: 31114324
pmcid: 6497853